Aptevo 3Q 2026: EPS ($5.19) — 10-Q Summary
Aptevo reported a wider net loss for 3Q 2026, driven by a $2.8M deemed dividend and lower expenses. EPS loss narrowed to $5.19 vs. $40.13 YoY. Clinical progress includes 79% CR/CRi rate in AML patients and Phase 1b completion targeted for 2026. APVO451 received a $1.5M grant for IND-enabling studies.
How this was made

The 30-second read
Why it matters
The earnings miss and loss expansion are likely to trigger a sell‑off, while the clinical data may provide a longer‑term upside narrative.
Market read
First‑report earnings for a micro‑cap biotech; material for traders focused on biotech earnings and clinical milestones.
What to watch
Potential future grant funding (Washington CARE Fund) and upcoming regulatory interactions could offset short‑term loss concerns.
Background
Aptevo Therapeutics filed its Q3 2026 10‑Q, summarizing financials and clinical updates.
Ticker impact
Aptevo reported a widened net loss and a diluted EPS of -$5.19 for Q3 2026, plus clinical trial data showing 79% CR/CRi in TP53‑mutated AML patients.
downward pressure as investors digest the larger loss and modest clinical progress.
The 10‑Q is the first public disclosure of these results; loss widening and weak EPS are material for a micro‑cap biotech.
Market effects
May dampen sentiment in the oncology biotech niche.
Limited to U.S. biotech investors.
Low; impact confined to APVO and similar small‑cap biotech stocks.
Counterpoint
Some investors may view the 79% CR/CRi rate as a positive catalyst despite the earnings miss.
Key entities
- companyAptevo Therapeutics Inc.
Biotech company developing targeted therapies for cancer.